Greenphire CEO Selected as Finalist in Ernst & Young Awards
News May 17, 2013
The awards recognize entrepreneurs that create and build market-leading businesses, taking standards of excellence to new heights and helping to transform the face of their respective industries. Sam was chosen from over 70 executives as a finalist for his achievements in building Greenphire into an industry leader.
Sam Whitaker, CEO of Greenphire, comments, "I am delighted to have been selected as a finalist by Ernst & Young and to be honored along with fellow nominees. As Greenphire grows and expands internationally, it is gratifying to be recognized for our successes in transforming outdated processes in the clinical trials industry. It would not have been possible without the tireless work of all the team members at Greenphire."
Since founding Greenphire, Sam has leveraged his entrepreneurial vision to simplify processes within clinical studies, replacing burdensome manual methods with platform-driven tools that execute complex payment processes globally. In five years he has built Greenphire from a two-person concept-driven start-up to an established player in the industry. The company now employs approximately 50 people on two continents.
Awards will be presented at a black tie gala on June 20 at the Pennsylvania Convention Center.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019